Drug Trial Radar · NCT06794554
Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options
Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jun 30, 2025
Primary completion
Nov 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Mundipharma Research LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jan 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to to evaluate the drug rezafungin in the treatment of Chronic Pulmonary Aspergillosis (CPA) in male and female patients aged 18 years and over with limited treatment options. The study aims to answer whether 6 months of rezafungin treatment is effective and safe in patients with chronic pulmonary aspergillosis with limited treatment options according to clinical and radiological response as measured by the St George's Respiratory Questionnaire, weight, and CT imaging. Participants will: * Be given the drug rezafungin every week for 6 months. * Visit the clinic once a month for checkups and tests. * Complete questionnaires on thier health and wellbeing.
Conditions
- Chronic Pulmonary Aspergillosis
Interventions
Rezafungin AcetateDrug
IV with a 400 mg loading dose on Day 1 of Week 1, followed by 200 mg once weekly, for a total of 26 doses (6 months).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in clinical and radiological response at 6 monthsTime frame: 6 months
Locations
37 sites in 10 countries. Site status is shown where the registry gives one.
Kepler University Hospital
Linz, Austria
Brussels University Hospital
Brussels, Belgium
UZ Gent
Ghent, Belgium
University Hospital Leuven
Leuven, Belgium
CHU UCL Namur
Yvoir, Belgium
CHU Amiens Picardie
Amiens, France
Institut Coeur Poumon CHU
Lille, France
CHU Arnaud de Villeneuve
Montpellier, France
CHU Bordeaux
Pessac, France
Evangelische Lungenklinik Berlin
Berlin, Germany
University of Cologne
Cologne, Germany
Asklepios Lungenfachklinik Gauting
Gauting, Germany
Országos Korányi Pulmonológiai Intézet
Budapest, Hungary
University of Genova, San Martino Hospital
Genova, Italy
University of Pisa
Pisa, Italy
INMI Lazzaro Spallanzaniconsu
Roma, Italy
Humanitas Research Hospital
Rozzano, Italy
Radboud Universitair Medisch Centrum Stichting
Nijmegen, Netherlands
Chonnam National University Hospital
Gwangju, South Korea
Seoul National University Bundang Hospital
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitari de Bellvitge
Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
Barcelona, Spain
Ramón y Cajal Hospital
Madrid, Spain
Hospital Sant Joan de Deu de Martorell
Martorell, Spain
Hospital La Fe
Valencia, Spain
Royal Papworth Hospital
Cambridge, United Kingdom
University Hospitals of Derby and Burton
Derby, United Kingdom
University of Dundee
Dundee, United Kingdom
Western General Hospital
Edinburgh, United Kingdom
Leeds Teaching Hospital
Leeds, United Kingdom
Imperial College Hospital
London, United Kingdom
Royal Brompton Hospital, Guy's and St. Thomas' Hospital
London, United Kingdom
University College London (UCL) Hospitals
London, United Kingdom
Manchester University Hospital
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.